A Systematic Review on the Current Landscape of T1 Bladder Cancer Substaging
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.T1 bladder cancer substaging improves outcome prediction. Micrometric methods are more reproducible than histometric techniques, suggesting standardization could enhance bladder cancer treatment.
Area Of Science
- Uro-oncology
- Cancer Staging
- Pathology
Background
- T1 bladder tumors exhibit heterogeneous behavior and prognosis, necessitating refined staging.
- Various substaging methods have been proposed to better stratify risk and guide treatment.
- Investigating the diagnostic and prognostic value of T1 substaging is crucial for improving oncologic outcomes.
Approach
- A systematic review of 63 studies (1990-2024) involving 8328 patients was conducted.
- Literature search included MEDLINE, EMBASE, and Cochrane Library databases following PRISMA guidelines.
- Studies focused on histometric and micrometric substaging techniques for T1 urothelial bladder cancer.
Key Points
- T1 substaging is a significant predictor of oncologic outcomes in bladder cancer.
- Micrometric substaging techniques demonstrate greater reproducibility and prognostic value compared to histometric methods.
- A lack of standardized, validated substaging systems hinders clinical application.
Conclusions
- Substaging T1 bladder tumors offers valuable prognostic information.
- Micrometric substaging appears superior for clinical utility and reproducibility.
- Standardization and validation of T1 substaging techniques could optimize bladder cancer management.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.